MyFinsight
Home
Blog
About
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$55,558K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Issuance of class a ordinary sha...
Proceeds from maturities of shor...
Issuance of class a ordinary sha...
Others
Negative Cash Flow Breakdown
Net loss
Purchase of short-term marketabl...
Trade and other payables
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-61,806
-69,707
-63,018
-167,303
Depreciation and amortization
896
845
751
745
Share-based compensation expense
2,546
13,355
3,590
3,709
Net periodic pension benefit gain (loss) for the qualified pension plan
9
11
-31
-18
Other non-cash items
-19
-422
92
-283
Other receivables
798
894
847
612
Operating lease right-of-use assets
-8
30
0
0
Prepaid expenses
-6,510
10,100
-3,857
-274
Other non-current assets
-1
749
0
-1,110
Trade and other payables
-6,342
-6,173
4,270
8,203
Operating lease liabilities
-395
-389
-377
-401
Accrued expenses and other current liabilities
3,794
7,123
-6,897
12,856
Net cash flow used in operating activities
-55,558
-66,286
-58,794
-44,543
Purchase of short-term marketable debt securities
58,748
59,068
59,167
0
Proceeds from maturities of short-term marketable debt securities
59,070
59,166
29,256
88,403
Purchase of property and equipment
0
0
0
0
Net cash flow provided by investing activities
322
98
-29,911
88,403
Proceeds from long-term debt, net of issuance costs
0
24,467
0
0
Issuance of class a ordinary shares under the sales agreement, net of transaction costs
44,312
6,007
-
0
Issuance of class a ordinary shares, net of transaction costs
-
-
72,395
-
Stamp duty on capital injection from moonlake to moonlake ag
-
-
0
0
Issuance of class a ordinary shares and pre-funded warrants under the 2026 offering, net of transaction costs
189,759
-
-
-
Proceeds from options exercised-Equity Incentive Plan
551
170
0
480
Proceeds from options exercised-Employee Stock Option Plan ESOP
0
0
0
100
Net cash flow provided by financing activities
234,622
30,644
72,395
480
Effect of movements in exchange rates on cash held
29
-483
91
-285
Net change in cash and cash equivalents
179,415
-36,027
-16,219
44,055
Cash and cash equivalents, beginning of period
298,490
334,517
350,736
180,426
Cash and cash equivalents, end of period
477,905
298,490
334,517
350,736
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Issuance of class a
ordinary shares and...
$189,759K
Issuance of class a
ordinary shares under the...
$44,312K
Proceeds from options
exercised-Equity Incentive Plan
$551K
Proceeds from maturities
of short-term...
$59,070K
(-83.16%↓ Y/Y)
Net cash flow
provided by financing...
$234,622K
(220.86%↑ Y/Y)
Net cash flow
provided by investing...
$322K
(-99.78%↓ Y/Y)
Effect of movements in
exchange rates on cash...
$29K
(-97.77%↓ Y/Y)
Canceled cashflow
$58,748K
Net change in cash
and cash...
$179,415K
(42.11%↑ Y/Y)
Canceled cashflow
$55,558K
Prepaid expenses
-$6,510K
(-282.35%↓ Y/Y)
Accrued expenses and
other current...
$3,794K
(212.65%↑ Y/Y)
Share-based compensation
expense
$2,546K
(-54.53%↓ Y/Y)
Depreciation and
amortization
$896K
(-20.00%↓ Y/Y)
Other non-cash items
-$19K
(-101.57%↓ Y/Y)
Net periodic
pension benefit gain...
$9K
(200.00%↑ Y/Y)
Operating lease
right-of-use assets
-$8K
Other non-current
assets
-$1K
(-100.06%↓ Y/Y)
Purchase of short-term
marketable debt securities
$58,748K
(-71.51%↓ Y/Y)
Net cash flow used in
operating activities
-$55,558K
(40.05%↑ Y/Y)
Canceled cashflow
$13,783K
Net loss
-$61,806K
Trade and other
payables
-$6,342K
(-178.42%↓ Y/Y)
Other receivables
$798K
(40.99%↑ Y/Y)
Operating lease
liabilities
-$395K
(11.04%↑ Y/Y)
Buy us a coffee